NOWINY LEKARSKIE 4 - Nowiny Lekarskie - UMP

376Teresa Kosicka, Hanna Kara-Perznych obserwowanych podczas terapii tymi lekami wporównaniu z innymi dotychczas stosowanymi antagonistamikanałów wapniowych.Piśmiennictwo1. Berdeaux A.: Dihydropyridines from the first to the fourthgeneration: better effects and safety. Therapie. 2003, 58, 4,333–339.2. Celentano A., Crivaro M., Perticone F. i wsp.: Antihypertensiveeffect of manidipine: 24 hours monitoring evaluationand Doppler-echocardiographic remarks. BloodPress., 1996, 5 Suppl. 5, 29–35.3. Watanabe H.: Block of T-type calcium channel by dihydropyridinecalcium antagonist. Teikyo Medical Journal. 2003,26, 6, 425–433.4. Herbette L.G., Vecchiarelli M., Sartani A. i wsp.: Lercanidipine:short plasma half-life, long duration of action and highcholesterol tolerance: updated molecular model to rationalizeits pharmacokinetic properties. Blood Press., 1998, 7 Suppl.2, 10–7.5. Masumoto K., Takeyasu A., Oizumi K. i wsp.: Studies ofnovel 1,4-dihydropyridine Ca antagonist CS-905. I: measurementof partition coefficient (logP) by high perfomanceliquid chromatography (HPLC). Yakugaku Zasshi. 1995, 115,3, 213–220.6. van der Lee R., Pfaffendorf M., van Zwieten P.A. i wsp.: Thedifferential time courses of the vasodilator effects of various1,4-dihydropyridines in isolated human small arteries are correlatedto their lipophilicity. J. Hypertens., 2000, 18, 11,1677–1682.7. Tikhonoff F., Mazza A., Casiglia E. i wsp.: Different effectsof manidipine and lercanidipine on blood pressure, peripheralcirculation and ankle oedema in hypertensive patients [abstract].14th European Meeting on Hypertension, 2004 Jun.13–17, Paris.8. Seravalle G, Stella ML, Foglia G. i wsp.: Temporal profile ofantihypertensive drug-induced regression of cardiac and vascularstructural alterations in hypertension [abstract no.P0780]. J. Hypertens., 2002;20 Suppl.4:S190-191.9. Fogari R., Zoppi A., Mugellini A. i wsp.: Effect of low-dosemanidipine on ambulatory blood pressure in very elderlyhypertensives. Cardiovasc. Drugs Ther., 1999, 13, 243–248.10. Cavallini A., Terzi G.: Effects of antihypertensive therapywith lercanidipine and verapamil on cardiac electrical activityin patients with hypertension: a randomized, double-blind pilotstudy. Curr. Ther. Resp., 2000, 61, 7, 477–487.11. Fogari R., Mugellini A., Zoppi A. i wsp.: Effect of manidipineand lisinopril on albuminuria and ventricular mass in diabetichypertensive patients with microalbuminuria [abstractno. P0209]. J. Hypertens., 2002, 20 Suppl. 4, 56.12. Sanchez A., Sayans R., Alvarez J.L. i wsp.: Left ventricularhypertrophy regression after a short antihypertensive treatmentwith lercanidipine vs enalapril [abstract no. 12]. FourthEuropean Meeting on Calcium Antagonists, 1999 Oct 27–29;Amsterdam.13. Fogari R., Mugellini A., Corradi L. i wsp.: Efficacy of lercanidipinevs losartan on left ventricular hypertrophy in hypertensivetype 2 diabetic patients [abstract no. P1.191].J. Hypertens., 2000, 18 Suppl. 2, S65.14. Nakaya H., Hattori Y., Nakao Y. i wsp.: Cardiac versus vasculareffect of a new dihydropyridine derivative, CV-4093.Eur. J. Pharmacol., 1988, 146, 1, 35–43.15. Angelico P., Guarneri L., Leonardi A. i wsp.: Vascularselectiveeffect of lercanidipine and other 1,4-dihydropyridinesin isolated rabbit tissues. J. Pharm. Pharmacol., 1999,51, 709–714.16. Sironi G., Colombo D., Greto L. iwsp.: Antihypertensive activityof lercanidipine and enantiomers in animal models.J. Cardiovasc. Pharmacol., 1997, 29 Suppl. 1, S33–40.17. Hayashi K., Ozawa Y., Fujiwara K. i wsp.: Role of actions ofcalcium antagonists on efferent arterioles, with special referencesto glomerular hypertension. Am. J. Nephrol., 2003, 23,229–244.18. Sabbatini M., Leonardi A., Testa R. i wsp.: Effect of calciumantagonists on glomerular arterioles in spontaneously hypertensiverats. Hypertension, 2000, 35, 775–779.19. Sabbatini M., Leonardi A., Testa R. i wsp: Effects of dihydropyridine-typeCa2+ antagonists on the renal arterial tree inspontaneously hypertensive rats. J. Cardiovasc. Pharmacol.,2002, 39, 1, 39–48.20. Kobayashi S., Hishida A.: Effects of calcium antagonists,manidipine, on progressive renal injury associated with mildhypertension in remmant kidneys. J. Lab. Clin. Med., 1995,125, 572–580.21. Reams G.P., Villarreal D., Wu Z. i wsp.: An evaluation of therenal protective effect of manidipine in the uninephrectomizedspontaneously hypertensive rat. Am. Heart. J., 1993,125, 2, 620–625.22. Martinez-Martin F.J., Saiz-Satjes M.: Addition of manidipinein type 2 diabetic patients with uncontrolled hypertension andmicroalbuminuria: the AMANDHA trial [abstract no.P2.334]. J. Hypertens., 2004, 22 Suppl. 245.23. Kanda T., Hayashi K., Ozawa Y. i wsp.: Role of T-type calciumchannels as a determinant of glomerular microcirculationand subsequent renal protection [abstract no. P0170].J. Hypertens., 2002, 20 Suppl. 4, S48.24. Rachmani R., Levi Z., Zadok B.S. i wsp.: Losartan and lercanidipineattenuate low-density lipoprotein oxidation in patientswith hypertension and type 2 diabetes mellitus: a randomizedprospective crossover study. Clin. Pharmacol.Ther., 2002, 72, 3, 302–307.25. Bellingieri G., Mazzaglia G., Savica V. i wsp.: Effect of manidipineand nifedipine on blood pressure and renal functionin patients with chronic renal failure: a multicenter randomizedcontrolled trial. Ren. Fail., 2003, 5, 5, 681–689.26. Robles NR, Ocon J, Gomez CF, Manjon M, Pastor L, HerreraJ. i wsp.: Lercanidipine in patients with chronic renal failure:the ZAFRA study. Ren. Fail., 2005, 27, 1, 73–80.27. Saku K., Zhang B., Hirata K. i wsp.: Effects of manidipineand delapril on serum lipids, lipoproteins, and apolipoproteinsin patients with mild to moderate arterial hypertension: a randomizedtrial with one-year follow-up. Clin. Ther., 1992, 14,6, 813–820.28. Suzuki S., Ohtomo M, Satoh Y. i wsp.: Effect of manidipineand delapril on insulin sensitivity in type 2 diabetic patientswith essential hypertension. Diabetes. Res. Clin. Pract., 1996,33, 43–51.29. Kohlmann O.J., Ribeiro A.B.: Manidipine in the treatment ofstage I and II essential hypertension patients with overweightor android obesity: a Brazilian multicentre study of efficacy,tolerabillity and metabolic effects. Arq. Bras. Cardiol., 2001,77, 5, 463–470.30. Notarbartolo A., Rengo F., Scafidi V. i wsp.: Long-term effectsof lercanidipine on the lipoprotein and apolipoproteinprofile of patients with mild-to-moderate essential hypertension.Curr. Ther. Res., 1999, 69, 4, 228–236.